Literature DB >> 8484584

Clinicopathologic findings after experimental implantation of synthetic intraocular lenses in dogs.

B C Gilger1, R D Whitley, S A McLaughlin, J C Wright, T R Boosinger.   

Abstract

Clinical findings indicate that canine eyes tolerate implantation of polymethylmethacrylate (PMMA) intraocular lenses (IOL) well, although inflammation and ocular damage attributable to the implants is not known. The use of silicone or polyhydroxyethylmethacrylate (HEMA) IOL has not been reported in dogs. In this study, 15 conditioned, mixed-breed dogs were allotted to 3 groups: 5 received PMMA IOL; 5 received silicone IOL; and 5 received HEMA IOL. The IOL optic was inserted into the anterior chamber of the right eye and anchored to the cornea. An identical surgical procedure was done on the left eye, except that no lens optic was inserted. Clinical examination and measurement of corneal thickness were done immediately prior to and after surgery. Aqueous humor samples were collected at the time of surgery and 28 days after surgery. Only mild and transient inflammation was observed in IOL-implanted eyes. On several postoperative days, it was found that PMMA IOL induced significantly greater corneal thickness, aqueous flare, anterior uveal irritation, and corneal edema than did other IOL. Significantly more anterior uveal irritation and increased aqueous humor protein concentration was observed with HEMA IOL than with PMMA or silicone IOL. Silicone IOL induced significantly less fibrin deposition than did PMMA or HEMA IOL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484584

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  1 in total

1.  Phacoemulsification and acryl foldable intraocular lens implantation in dogs: 32 cases.

Authors:  Na Young Yi; Shin Ae Park; Man Bok Jeong; Won Tae Kim; Se Eun Kim; Je Min Chae; Kang Moon Seo
Journal:  J Vet Sci       Date:  2006-09       Impact factor: 1.672

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.